307
positive ISA report for "Steady Stomach" CBD combination. FSD has also launched a clinical trial on Irrital Bowel Syndrome.
To summarize: An expert team at the helm; a relatively low market cap compared to the valuation of its assets and potential; a focus on high marigins (medical stream, oils, capsules, derivatives); key strategic parternerhships; and a forward thinking anticipatory approach.
I hope the above summary when combined with the our industry leading content including best in class stock lists causes you reason to conduct additional due dilligence on consdiering FSD Pharma’s role in your investment portfolio. But remember, this is not investment advice and is provided simply for discussion and awareness purposes. The company was unware of this case study and as such did not provide input, content, or financial consideration.